Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)

May 16, 2024

https://www.globenewswire.com/news-release/2024/05/16/2883372/0/en/Ardelyx-Presents-Additional-Data-at-the-NKF-2024-Spring-Clinical-Meetings-on-XPHOZAH-tenapanor.html

WALTHAM, Mass., May 16, 2024 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of XPHOZAH® (tenapanor) was presented in a series of poster presentations at the National Kidney Foundation (NKF) 2024 Spring Clinical Meetings, now underway in Long Beach, California. Ardelyx is also hosting an Exhibitor Showcase discussing hyperphosphatemia management.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.